212 results about "Hepatoma cell line" patented technology

The present invention relates to a compound of Antrodia camphorata used to inhibit HBV, in particular to an extract, 4-hydroxy-2,3-dimethoxy-6-methyl-5(3,7,11-trimethyl-dodeca-2,6,10-trienyl)-cyclohex-2-enone which is isolated from Antrodia camphorata, and its use in inhibiting HBV effectively. The cyclohexenone compound according to the present invention showed cytotoxicity on HBV-secreting human hepatoma cell line HepG2 2.2.15, decreased synthesis of HBV particles, further inhibited synthesis of HbsAg and HbeAg effectively to achieve the goal of HBV inhibition.

The invention belongs to the technical field of the molecular biology and the biomedicine, and particularly relates to application of a gRNA sequence based on a CRISPR / Cas9 system to cause tumor cell apoptosis. According to the design principle of CRISPR / Cas9, two target points are designed on a human genome, and corresponding oligos is synthesized and established on a px458 carrier. The CRISPR / Cas9 system guided by the gRNA is established in a human hepatoma cell line (HepG2) according to the design of the two target points, a human TCAB1 gene can be effectively knocked out, the system is easy to operate, and the knockout efficiency of the human TCAB1 gene is high. The CRISPR / Cas9 system guided by the gRNA can be expected to be applied in novel tumor treating medicine.

The invention relates to a newly cloned full-length sequence of a long chain non-coding RNA (Ribonucleic Acid) gene and an application method thereof. The gene can be detected in a separation sample by methods including a hybrid method or an amplification method; and the gene can be used as a tumor marker, in particular a marker of liver cancer. According to the gene sequence, a real-time quantification PCR (Polymerase Chain Reaction) primer and an in situ hybridization probe are designed and synthesized; and by detecting the expression level of the long chain non-coding RNA in a liver cancer clinical case sample, expression of the long chain non-coding RNA in liver cancer is up-regulated remarkably, and prognosis of patients with liver caner with high expression of long chain non-coding RNA is poorer. According to the gene sequence, a RNA eukaryotic expression vector in a short hairpin structure for closing the expression of the long chain non-coding RNA by RNA interference is designed and synthesized; and the expression of the long chain non-coding RN in a liver cancer cell line A is inhibited successfully by using the vector.

The invention discloses a single-stranded deoxyribonucleic acid (ssDNA) aptamer targeting human highly metastatic hepatoma carcinoma cell and an application of the ssDNA aptamer, and relates to the field of diagnosis and treatment of the recurrence and metastasis of the hepatocellular carcinoma, so that the high-efficient novel specific molecules are provided for the diagnosis and treatment of the recurrence and metastasis of the hepatocellular carcinoma. According to the invention, a subtractive cell-SELEX technology is applied, two hepatoma carcinoma cell systems with same genetic background and obviously different metastatic potentials are a subtractive target and a screening target, respectively, and the hepatoma carcinoma cell systems are MHCC97-L (low metastasis) and HCCLM9 (high metastasis), so that the ssDNA aptamer is capable of specifically recognizing the highly metastatic potential hepatoma carcinoma cell HCCLM9. The aptamer is a single-stranded DNA molecular probe capableof specially combining with a surface of a human highly metastatic hepatoma carcinoma cell membrane, and a nucleotide sequence of aptamer is represented by SEQ ID No.1. The aptamer is expected to play an important role in preparation of a reagent for diagnosing or treating the hepatocellular carcinoma.

The invention belongs to the field of biomedical science, and aims to provide a high metastatic potential hepatoma cell line capable of steady autophagy indication, and an establishment method and an application method thereof. Lentivirus expression vectors containing EGFP (enhanced green fluorescent protein)-LC3 (light chain 3) autophagy reporter genes are constructed and used to infect hepatoma cells with high metastatic potential, so that host cells can express the EGFP-LC3 steadily and efficiently and indicate autophagy changes of the hepatoma cells steadily. To apply the cell line, metastasis research models can be established in vitro and in vivo for the observation on autophagy changes during metastasis, and the cell autophagy changes can be analyzed rapidly and quantitatively by adopting an image analysis method based on Top-hat operators and morphological filter. The high metastatic potential hepatoma cell line has the characteristics that autophagy indication is conducted steadily, reliably and sensitively in a real-time manner, the metastasis occurs definitely, the autophagy is quantified rapidly and accurately, the operation is simple and convenient, and the like, and can greatly facilitate correlation study on autophagy and metastasis.

The invention relates to the technical field of medicaments. Dimethyldiguanide belongs to a biguanides oral hypoglycemic medicament and is widely applied to pharmaceutical therapy of type 2 diabetes. The invention aims at providing a novel application of the dimethyldiguanide and particularly an application of the dimethyldiguanide in preparation of medicaments for preventing or treating the hepatocellular carcinoma. According to the application disclosed by the invention, the restriction effect of the dimethyldiguanide on the hepatocellular carcinoma is found by research from two aspects, namely, cell culture in vitro and animal experiment in vivo. Experiments find that the dimethyldiguanide has the capabilities of restricting proliferation and clone formation of a hepatocellular carcinoma cell line and causing the cell cycle arrest and apoptosis increase of the hepatocellular carcinoma cell line, and also has the capability of enhancing the hepatocellular carcinoma resisting effect of chemotherapeutics when combined with the chemotherapeutics, such as cis-platinum, doxorubicin and the like. The invention provides the novel application of the dimethyldiguanide and also provides a novel concept for prevention and treatment of the hepatocellular carcinoma.

The invention relates to an application method of a newly cloned long-chain non-coding ribonucleic acid (RNA) gene, in particular to the application method of the long-chain non-coding RNA method in preparation of an interference inhibitor. The application method of the long-chain non-coding RNA method in preparation of the interference inhibitor comprises designing and combining a short hairpin structure RNA eukaryotic expression vector for closing expression of the long-chain non-coding RNA in an RNA interference mode according to a gene sequence of the long-chain non-coding RNA, and using the short hairpin structure RNA eukaryotic expression vector to successfully restrain the expression of the long-chain non-coding RNA in a liver cancer cell line.

The invention discloses a raja porosa cartilage polypeptide angiogenesis inhibitory factor and a preparation method and application thereof. The amino acid sequence of the polypeptide angiogenesis inhibitory factor is Gly-Glu-Glu-Gly-Thr-Met-Gly-Leu (GEEGTMGL), and in ESI / MS detection, a molecular ion peak of m / z 793.11 Da ([M+H]<+>) is given out; the raja porosa cartilage polypeptide angiogenesis inhibitory factor Gly-Glu-Glu-Gly-Thr-Met-Gly-Leu (GEEGTMGL) can effectively inhibit angiogenesis of a chick chorioallantoic membrane (CAM) and proliferation of a human lung cancer cell A-549 and a human hepatoma cell line Bel-7402. The raja porosa cartilage polypeptide angiogenesis inhibitory factor Gly-Glu-Glu-Gly-Thr-Met-Gly-Leu (GEEGTMGL) can be used for preparation of drugs for inhibiting angiogenesis and preventing and treating tumors.

Leptin was previously demonstrated to exert potent immune modulatory properties in several immune mediated disorders. The aim of the study was to determine leptin's anti-tumor effect in a murine model of human hepatocellular carcinoma (HCC). In vivo, Athymic T cell deficient (nude) mice transplanted with 1×106 human Hep3B cells, followed by administration of two daily intraperitoneal doses of 0.5 mg / gram leptin for 6 weeks. Leptin administration induced a significant reduction in tumor size and improved survival in nude mice. Histologically, tumors of leptin-administered mice featured increased inflammatory exudate in interphase areas. Leptin-induced tumor suppression was associated with a significant increase in peripheral natural killer (NK) cell number. Splenocytes from leptin-treated mice featured decreased expression of CIS mRNA. To determine which lymphocyte subset is a prerequisite for the anti tumor effect of leptin, T&B cell deficient (Scid) mice and T,B& NK deficient (Scid-Beige) mice were subcutaneously implanted with Hep3B tumor cells, with and without the daily intraperitoneal administration of 0.5 mg / gram leptin for 6 weeks. SCID mice featured leptin-associated tumor suppression similar to those of nude mice. In contrast, NK-deficient SCID-Beige mice developed larger tumors. To further establish natural killer cell's central role in mediation of leptin's anti-tumor effect, NK cells were incubated in vitro with increasing doses of leptin, demonstrating a dose-dependent increase in cytotoxic activity. Incubation of leptin with hepatoma cell line was found to induce a dose-dependent reduction in hepatoma cell proliferation, suggesting an additive direct anti-tumor effect. Further synergism in inhibition of hepatoma cell proliferation in vitro was achieved following addition of natural killer cells. HCC cells expressed leptin receptor mRNA, while addition of leptin induced increased mRMA expression of STAT2 and SOCS1 on tumor cell lines. Leptin administration induces a significant suppression of human HCC. This effect is mediated by induction of natural killer cell proliferation and activation, and by direct inhibition of tumor growth. Decreased natural killer cell expression of inhibitory CIS protein and over expression of the anti-proliferative STAT2 and SOCS1 proteins in HCC lines may underline both anti cancerous effects of leptin.

The invention belongs to the field of micro-organism animal cell line and relates to a human hepatoma cell line which can emit high-intensity red or green fluorescence and has high transferring ability of lung and lymph node metastasis, and a method for establishing the same. The method comprises the following steps: using the human hepatoma cell line HCCLM3 and HCCLM6 which have high transferring ability of the lung and lymph node metastasis as mother cells, performing cotransfection on plasmid DNA of 239 cells through slow virus packaging plasmids to obtain false slow virus particles by expressing red or green fluorescent protein genes through eucaryon, and infecting liver cancer cell strains of the mother cells to obtain the chromosome integrated hepatoma cell line which has high transferring ability of the lung and lymph node metastasis and can stably expressing the red or the green fluorescence. The human hepatoma cell line which has high transferring ability of the lung and lymph node metastasis in vitro can be applied to the tracer studies on tumor cells, the molecular mechanism studies on the recurrence and transferring of liver cancer, as well as the pre-clinical drug efficacy studies on new anti-tumor drugs, thus the human hepatoma cell line has wide application prospect.

The invention provides establishment and application of a hepatocellular carcinoma cell line HCC-LY10. Specifically, the hepatocellular carcinoma cell line HCC-LY10 provided in the invention has stable traits, can be subcultured stably and repeatedly, and is applicable to established animal models of hepatocellular carcinoma, thus being an ideal cell line for the basic and preclinical phase application study of hepatocellular carcinoma. In addition, the hepatocellular carcinoma cell line HCC-LY10 partially expresses hepatocellular carcinoma stem cell marker EpCAM. The invention also provides application of the cell line in establishing model animals, screening drugs, and other aspects.

The invention relates to a phenothiazine compound and a preparation method thereof. The invention further relates the application of the phenothiazine compound in anti-cancer drug preparation and anti-cancer drugs using the compound as the effective component. The phenothiazine compound has the advantages that the compound with broad-spectrum anti-cancer effect is obtained by modifying phenothiazine ternary interlink parent nucleuses, synthesizing method is simple, and high yield is achieved; the phenothiazine compound has certain restraining effect on human breast cancer cells line MCF-7 and human hepatoma cell line Hep-G2, and a new thought is provided to new drugs satisfying clinic requirements.

The invention belongs to the field of microorganism animal cell system, and relates to an establishment method of a fluorescence visualization human hepatoma nude mice model which can self emit high strength red or green fluorescences and has the metastatic ability. After obtaining a human high-metastatic fluorescence hepatoma cell line HCCLM3-R, HCCLM3-G, HCCLM6-R and HCCLM6-G of fluorescence genes with high chromosome conformable degree, high fluorescence intensity and stable expression by using the method of pseudotype slow virus infection, hepatoma cells expressed by the fluorescences is placed beneath nude mice skin to establish a fluorescence visualization high-metastatic human hepatoma nude mice subcutaneous tumor model or subcutaneous fluorescence expression tumor tissues is placed in nude mice hepar to establish a fluorescence visualization high-metastatic human hepatoma nude mice hepar primary tumor model. The got model can be used as a tracer of animal in vivo hepatoma cells, and can be used for molecular mechanism study of hepatoma recurrence and metastatic and prophase therapeutic effect discrimination for new anti-hepatoma therapy and new anti-hepatoma drugs, etc.

The present invention discloses a cyclic pentapeptide with anti-tumour activity, which is cyclic (leucyl-N-methylleucyl-leucyl-leucyl-N-methylleucyl) and the constitutional formula of which is shown in the formula (I). The cyclic pentapeptide of the present invention is separated from galaxaura filamentosa in the South China Sea, and in vitro experiments show that the cyclic pentapeptide has strong inhibiting effect on human hepatoma cell lines (HepG2), human hepatoma cell lines (BEL-7402), human mammary cancer cell lines (MCF-7), human colon cancer cell lines (LOVO), human lung cancer cell lines (PC84045) and human nasopharyngeal cancer (CNE) and can keep the mitotic cycle of BEL-7402 hepatoma cells in G2 / M phase. The present invention provides a pilot compound for the research and the development of new anti-tumour drugs and is valuable for the exploitation of the marine pharmaceutical resources of China.

The invention discloses dehydroabietic acid benzimidazole derivatives with antitumor activity as well as a preparation method and an application of the dehydroabietic acid benzimidazole derivatives. The dehydroabietic acid benzimidazole derivatives I-a to I-l with the structures shown in a general formula I and pharmaceutically acceptable salt of the derivatives are shown in the description, wherein corresponding Aryl of dehydroabietic acid benzimidazole derivatives I-a to I-l are shown in the description respectively. Nitrogen-containing heterocyclic compounds are pharmaceutically acceptable salt of the dehydroabietic acid benzimidazole derivatives and have good antitumor bioactivity. Pharmacology experiments prove that the compounds have a remarkable inhibition effect on hepatoma cell lines SMMC-7721, breast cancer cell lines MDA-MB-231 and colon cancer cell lines CT26.

The invention provides application of polyguluronate sulfate to anti-hepatitis B virus medicine preparation. Experiments prove that the polyguluronate sulfate is capable of well inhibiting expression of an HBV (hepatitis B virus) HBsAg (hepatitis B surface antigen) and an HBV HBeAg (hepatitis Be antigen) in a hepatocellular carcinoma cell line HepG2.2.15, remarkably inhibiting expression of HBV-S mRNA (messenger ribonucleic acid) in the hepatocellular carcinoma cell line HepG2.2.15, enhancing generation and secretion of anti-virus immunity-associated IFN (interferon)-beta in cells and activating NF (nuclear factor)-kappa B and MAPK (mitogen-activated protein kinase) signal pathways. The polyguluronate sulfate which is a marine sulfated polysaccharide compound has the advantages of rich resources, low cost, high safety and the like, and is obviously superior to positive control drug lamivudine in anti-HBV effect, thereby being promising in application prospect of anti-hepatitis B virus medicine preparation.

The invention relates to application of compounds and salt thereof, and particularly relates to application of matrine compounds and salt thereof in preparation of anti-hepatic fibrosis and anti-liver cancer medicaments. The compounds have the advantages of remarkably inhibiting the proliferation of hepatoma cell lines Hep-G2, Hun-7, MHCC-97L, SMMC-7721 and Hep-3B and proliferation activities of fibroblast BJ, human hepatic stellate cells LX-2 and hepatic stellate cells HSC-T6, and can be used for preparing medicaments for treating hepatic fibrosis and liver cancer.

The invention belongs to the technical field of cell biology and in particular relates to a hepatoma cell aptamer sequence and an application thereof. A characteristic sequence TTTTTT specifically bound with HepG2 is prepared by screening an aptamer specifically bound with a human hepatoma cell line HepG2. The characteristic sequence is the basis of specific binding of the aptamer and the human hepatoma cell line HepG2, can be used for design and preparation of targeted drugs, preparations or other products for resisting hepatoma, and can serve as a molecular probe or target for resisting hepatoma. The characteristic sequence provides a powerful support for molecular diagnosis and targeted therapy of hepatoma and has important clinical values.

The invention discloses a traditional Chinese medicinal composition for treating lung cancer and liver cancer. The composition consists of rhizoma paridis yunnanensis extract, rhizoma curcumae longae extract and white paeony root extract according to a mass ratio of 1:(15-25):(5-15). Experiments prove that the traditional Chinese medicinal composition can obviously inhibit lung cancer cell lines such as LA795 and hepatoma cell lines such as Hep-B3 from growing, the half maximal inhibitory concentrations (IC50) of the lung cancer cell lines and the hepatoma cell lines can respectively reach below 20 micrograms / milliliter; tests on mouse models bearing lung adenocarcinoma and liver cancer tumors show that the lung adenocarcinoma and liver cancer inhibition rates are respectively above 50%, and the spleen index and liver index of mice are increased; and compared with raw medicinal materials which are separately applied, the medicinal composition has high anti-lung cancer and anti-liver cancer activities, an exact effect and a good inhibition effect on lung cancer and liver cancer.

The invention provides 2-arylamine pyrimidine derivatives containing hydroxamic acid fragments shown in the formulas I and II. 2-arylamine pyrimidine containing carboxyl fragments is mainly used as a parent nucleus and is subjected to single-step condensation and related modification with hydroxylamine protected by THP to obtain a target compound. An experiment proves that the derivatives has the remarkable anti-proliferative effect on tumor cells (an overexpression EGFR human epidermal carcinoma cell line A431 and a human pulmonary carcinoma cell line H1975 resisting Gefitinib) related to EGFR tyrosine kinase activity on the cellular level, and tumor cells (a human cervical carcinoma cell line Hela, a human hepatoma cell line HepG2, a human promyelocytic acute leukemia cell line HL60, a human oral epidermoid carcinoma cell line KB, a human colon cancer cell line SW620) related to the HDAC histone acetylase activity, and the corresponding medicine for resisting cancer cells can be prepared. The general structural formula is shown in the description.

The invention discloses a tetrandrine derivative with antitumor activity and a preparation method thereof. The structural formula of the compound is shown in the specification. The preparation method comprises the following steps: dissolving bisbenzylisoquinoline compound serving as raw material in certain solvent; adding an alkali reagent and a reactant Y, and mixing; reacting for 0.1 to 72 hours under temperature of -20 to 300 DEG C; neutralizing the reacted solution with acid, and then separating and purifying to prepare the objective product. The tetrandrine derivative prepared by the invention can well inhibit proliferation of human hepatoma cell line HepG2 and pancreatic cancer cell SW1990, and can be used for preparing antitumor medicines.

The invention relates to a preparation method and application of a dihydroporphine photosensitizer and a dihydroporphine sonosensitizer belonging to the chemical medicine field. The compounds have the general formula as shown in the specification, and the dihydroporphine photosensitizer and sonosensitizer compounds have different degrees of inhibition effects on human hepatoma cell line Hep G2 in in-vitro antineoplastic activity assessment. The ratios of optical activity to dark activity and sound activity to dark activity are higher than that of hematoporphyrin monomethyl ether as a positive control, and the method can be used for preparation of the photosensitizer and the sonosensitizer for photodynamic therapy sonodynamic therapy method for cancer treatment.

The invention relates to bisbenzylisoquinoline quaternary ammonium salt as well as a preparation method and an application thereof in preparing an antitumor drug. A structure of the bisbenzylisoquinoline quaternary ammonium salt is shown in a general formula (I) described in the specification and a substituent group is shown in the specification. The bisbenzylisoquinoline quaternary ammonium salt disclosed by the invention is applied to preparation of an antitumor drug. The compound disclosed by the invention, which has a bisbenzylisoquinoline parent nucleus structure and has the characteristics of ester quaternary ammonium salt, has achieved a pancreatic cancer cell SW1990 proliferation inhibiting rate above 50% and a hepatoma cell line HepG2 inhibiting rate above 50% as well when the compound is 0.5ug / ml, and activity of the compound is much higher than that of an existing tetrandrine compound.

The invention belongs to the technical field of duck plague virus culturing, particularly relates to a new host cell of the duck plague virus, and discloses application of a chicken liver cancer cell system as a duck plague virus host. A traditional method for culturing the duck plague virus through the duck embryo fibroblast primary cell is limited by duck embryo supply and the hatching day age, and wastes time and labor during preparation. The established method for culturing the duck plague virus chicken liver cancer cell system is good in virus growth. The method for culturing the virus through a continuous cell line is not influenced by duck embryo supply, and has the advantages of being instantly available and capable of saving time and labor. The duck plague virus can grow and reproduce on a chicken liver cancer cell system continuous cell culture medium, and by means of a newly-found virus copying host cell, a new technical approach, method and material are provided for research of related fields.

The present invention relates to an application of bone morphogenetic protein 4 in cancer inhibition. Specifically bone morphogenetic protein (BMP) has a liver cancer stem cell differentiation induction effect, wherein CD133 protein expression of liver cancer cell lines can be down-regulated and liver cancer cell line CD133+ liver cancer stem cell differentiation can be promoted with BMP4, and BMP4 can further be provided for inhibiting in vitro proliferation and self-renewal of liver cancer cell lines and inhibiting tumorigenicity of immune-deficient mice. The present invention further provides BMP4-induced liver cancer stem cell differentiation action mechanism.

The invention discloses a RNA has-miR-29c related to Hepatitis B Virus (HBV) and liver cancer and its uses in inhibiting HBV infection and preventing liver cancer from generation. The invention is directed to the field of biology technology research. Based on qRT-PCR technology, it is found that compared to a hepatocyte lineage HepG2, the has-miR-29c has a down-regulation of expression in a hepatoma cell line. A bioinformatics method and double fluorescence detection are used to determine that the target gene of has-miR-29c is Tnfaip3. The has-miR-29c expression carrier is externally transfected. It is observed that miR-29c can inhibit the growth of tumor cells for a short period and has a certain inhibition effect to the duplication and expression of HBV DNA. The target gene Tnfaip3 has a down-regulation of expression both on mRNA and the level of protein. The research result shows miR-29c possibly participates in the generation and development process of liver cancer related to HBV through its target gene Tnfaip3. Therefore, miR-29c can be used as a regulation and control molecule for inhibiting HBV infection and preventing liver cancer from generation, thereby providing a theoretical and experimental basis for clinic prevention and treatment.

The present invention relates to the field of microbial animal cells, and specifically a hepatoma cell line STL-C1 derived from human hepatoma para-carcinoma tissue. The cell line has a preservation number CCTCC No:C201630. The present invention also provides an establishment method and application of the cell line. The established hepatoma cell line STL-C1 is derived from human hepatocellular hepatoma para-carcinoma tissue, and can be cultured in vitro for a long term and has stable passage; and in vivo experiments show that the cell line still has good tumorigenic property, and is completely different from the currently existing established common hepatoma cell lines and even from the hepatoma cancer embolus cell line. The hepatoma cell line STL-C1 has important usage and reference value to the study of the formation of satellite lesions, and biological behaviors suahc as recurrence and transfer of primary hepatic carcinoma, is a novel cell model for basic and clinical research of hepatoma, and has broad application prospects.

The invention discloses an Luc-GFP marked high-transitivity human hepatoma cell line. Hepatoma cells are taken as mother cells, a virus solution packaged with pCDH-CMV-Luc-EF1-GFP-Puro is transfectedthrough slow viruses, and then through puromycin screening, the high-transitivity human hepatoma cell line with stable GFP expression and luciferase activity is obtained. By using the Luc-GFP marked high-transitivity human hepatoma cell line, an in situ hepatoma model for a naked mouse is established through a cell suspension method and a tumor tissue block conversion method respectively, the tumor formation rate of the hepatoma model is 100% respectively, the rates of lung metastasis are 100% and 80% respectively, a foundation is laid for monitoring the growth of tumor in the level of livinganimals and evaluating the curative effect of hepatocellular carcinoma metastasis resistant medicine, and the cell line has greater application prospect.

The invention discloses an application with hibiscus peel acetic acid to evoke tumor cell to die, which is characterized by the following: extracting effective element of hibiscus peel acetic acid from hibiscus peel; using hibiscus peel acetic acid to antimycotics haemostasis, nerve dermitis and so on aspects; unknowing making mechanism of hibiscus peel; restricting development of hibiscus peel . This invention can resolve the above problems.